Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma. (linkinghub.elsevier.com)

Authors: Goulding JR … Durinck K Journal: Cell Reports Published: 2026-10-12 DOI: https://doi.org/10.1016/j.celrep.2026.117997